3 New Strong Buy Ratings from Top-Rated Analysts: 10/10/2025

By Mijuško Šibalić, Stock Market Writer and Stock Researcher

October 10, 2025 5:39 AM UTC

3 New Strong Buy Ratings from Top-Rated Analysts: 10/10/2025

There’s still time to check out these tickers before the market close … All sourced from our Strong Buy Stocks from Top Wall Street Analysts screener:

Artivion (AORT) just got a notable price target hike
Insulet (PODD) is well-positioned in a market with growing demand
Ardent Health Partners (ARDT) is a fairly new issue, but has myriad strong points

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

Here's the Best Day to Buy Stocks Did you know the S&P 500 has a 100% history of soaring, beginning on one particular day every fall? We call this the "Green Day phenomenon." It works on 5,000 stocks. For example, Nvidia has a 100% history of soaring beginning on one particular day every single year. Click here to see the green days for 7 major stocks today.

1. Artivion (NYSE: AORT)

This medical device business specializes in cardiac and vascular valves, stent grafts, and surgical sealants. Artivion is also one of the leading providers of cryopreserved human tissues for cardiac and vascular repair, giving it a unique position in both traditional devices and biologics. Beyond great growth prospects, AORT is also notable for the high degree of insider buying tied to the stock as of late.

Zen Rating: B (Buy) — see full analysis >

Recent Price: $40.74 — get current quote >

Max 1-year forecast: $50.00

Why we’re watching:

AORT shares have 2 Strong Buy ratings, 2 Buy ratings, and 1 Hold rating. See the ratings
Stifel Nicolaus researcher Rick Wise (a top 10% rated analyst) recently maintained a Strong Buy rating on the stock, and increased his price target from $40 to $46.
Wise attributed their price target hikes to "checks with five cardiac surgeons about their latest On-X utilization trends.
The analyst detailed that the physicians provided "constructive commentary" and said the broader cardiac surgeon community could be reacting incrementally more positively to the data in a 2025/01 JACC medical journal paper.
William Plovanic of Canaccord Genuity (a top 15% rated analyst) also reiterated a Strong Buy rating on Artivion shares recently, and hiked his price target from $41 to a Street-high $50.
Plovanic attributed their price target hike to Artivion's market cap move.
AORT currently ranks in the top 10% of the equities tracked by our system, giving it a Zen Rating of B.
In terms of Sentiment, Artivion ranks in the 84th percentile — a key contributing factor being the fact that 31.69% of the insider transactions tied to the stock in the past 12 months have been purchases.
With that being said, Growth is the star of the show here — as AORT ranks in the top 3% in that category. (See all 7 Zen Component Grades here >)

2. Insulet (NASDAQ: PODD)

Insulet has carved out a strong niche for itself in the diabetes technology market through Omnipod, its tubeless, wearable insulin pump. Wall Street equity researchers expect a lot of upside from Insulet — and one top analyst believes that the aforementioned strong niche will blossom into full-blown dominance.

Zen Rating: B (Buy) — see full analysis >

Recent Price: $310.19 — get current quote >

Max 1-year forecast: $399.00

Why we’re watching:

Analyst coverage of PODD is quite bullish — the stock has 5 Strong Buy ratings, 4 Buy ratings, and 1 Hold rating.: See the ratings
The average 12-month price forecast for Insulet shares currently stands at $359.90, and implies a hefty 16.57% upside.
Canaccord Genuity researcher William Plovanic (a top 15% rated analyst) recently maintained a Strong Buy rating on the stock and increased his price target from $353 to a Street-high $399.
Plovanic said they hiked their price target on Insulet because Canaccord Genuity updated its model on the name to account for new revenue guidance and commentary from recent investor conferences.
The analyst argued that Insulet is well-positioned to win in the insulin pump market with its differentiated form factor and first-mover advantage in the T2D market.
PODD ranks in the top 10% of the stocks that we track, giving it a Zen Rating of B. Stocks with this distinction have provided an average annual return of 19.88% since the early 2000s.
Insulet shares currently rank in the 78th percentile of the equities that we track in terms of Growth.
Another key advantage is the company’s strong balance sheet — when it comes to Financials, PODD ranks in the top 10% of stocks.
Our Artificial Intelligence Component Grade rating uses a neural network trained on more than 20 years of fundamental and technical data to identify likely outperformers. In this category, Insulet ranks in the top 9%. (See all 7 Zen Component Grades here >)

3. Ardent Health Partners (NYSE: ARDT)

Fresh off its IPO, Ardent Health Partners is still flying under the radar despite being one of the largest for-profit hospital operators in the U.S. With 30 hospitals and over 200 care sites across six states, Ardent is positioned at the intersection of regional healthcare demand and efficient, scalable operations. The price of ARDT shares has fallen significantly since they’ve gone public — and present prices present a rather attractive entry point.

Zen Rating: A (Strong Buy) — see full analysis >

Recent Price: $13.40 — get current quote >

Max 1-year forecast: $21.00

Why we’re watching:

Ardent Health Partners has 4 Strong Buy ratings, 2 Buy ratings, and 1 Hold rating. See the ratings
The average price target for ARDT shares, currently pegged at $18.08, implies a hefty 38.19% upside.
UBS researcher A.J. Rice (a top 12% rated analyst) recently initiated coverage on the stock with a Strong Buy rating and a $17 price target.
ARDT is currently the 2nd highest-rated stock in the Medical Care Facility industry, which has an Industry Rating of A.
Ardent Health Partners ranks in the top 1% of the stocks that we track — in fact, it is currently rated 31st overall out of roughly 4,600.
In terms of its Financials Component Grade rating, ARDT ranks in the 91st percentile of equities.
Safety is another strong point — in this category, Ardent Health Partners ranks in the top 6%.
When it comes to both Sentiment and Value, ARDT ranks in the top 1% — the former is owed to the fact that 41.73% of the insider transactions tied to the stock in the past 12 months have been purchases, while the latter is owed to a very attractive 7.03x price-to-earnings (P/E) ratio. (See all 7 Zen Component Grades here >)